Get the Stockscreener App
2.81
3.31%
0.09
Inhibikase Therapeutics Inc stock is traded at $2.81, with a volume of 126.28K.
It is up +3.31% in the last 24 hours and down -12.19% over the past month.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
See More
Previous Close:
$2.72
Open:
$2.76
24h Volume:
126.28K
Relative Volume:
0.40
Market Cap:
$194.91M
Revenue:
-
Net Income/Loss:
$-19.20M
P/E Ratio:
-0.8413
EPS:
-3.34
Net Cash Flow:
$-15.98M
1W Performance:
+5.64%
1M Performance:
-12.19%
6M Performance:
+87.33%
1Y Performance:
+63.42%
1-Day Range:
$2.62
$2.89
1-Week Range:
$2.55
$2.90
52-Week Range:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
678-392-3419
Address
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
Compare IKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
2.81 | 194.91M | 0 | -19.20M | -15.98M | -3.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inhibikase Therapeutics Inc Stock (IKT) Latest News
Bullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of Stock - Yahoo Finance
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR
Inhibikase Therapeutics Completes Amendment to Certificate of IncorporationAtlanta, Georgia – Inhibikase Therapeutics, Inc. (NYSE:IKT) recently announced the successful completion of a Special Meeting of Stockholders on January 3, 2025. During this m - Defense World
Inhibikase Therapeutics expands authorized shares - Investing.com India
Inhibikase Therapeutics expands authorized shares By Investing.com - Investing.com Australia
Contrasting CRISPR Therapeutics (NASDAQ:CRSP) & Inhibikase Therapeutics (NYSE:IKT) - Defense World
Inhibikase Therapeutics (NYSE:IKT) Trading 3.4% HigherTime to Buy? - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Trading 3.4% Higher – Still a Buy? - Defense World
Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com
Inhibikase Therapeutics Hits 52-Week High, Surpassing Market Expectations with 198% Growth - mediahousepress
Inhibikase stock soars to 52-week high, hits $3.88 - Investing.com
Inhibikase Therapeutics Terminates At the Market Offering Agreement - Defense World
Inhibikase Therapeutics ends agreement with sales agent By Investing.com - Investing.com Canada
Inhibikase Therapeutics ends agreement with sales agent - Investing.com
Inhibikase Therapeutics (NYSE:IKT) Stock Price Up 7% – What’s Next? - Defense World
Inhibikase Therapeutics (NYSE:IKT) Shares Up 7%Here's Why - MarketBeat
Inhibikase: Potential To Improve Current Treatment Options For PAH Patients - Seeking Alpha
Inhibikase Therapeutics files to sell 58.31M shares of common stock for holders - TipRanks
ARMISTICE CAPITAL, LLC Expands Stake in Inhibikase Therapeutics Inc - GuruFocus.com
Inhibikase Therapeutics Inc (IKT) Quarterly 10-Q Report - Quartzy
Inhibikase Therapeutics Reports Q3 2024 Financial Results - TipRanks
Inhibikase Therapeutics reports Q3 EPS (65c), consensus (48c) - TipRanks
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity - The Bakersfield Californian
Inhibikase Secures $275M Financing Deal, Advances PAH Drug Trial Despite Q3 Loss | IKT Stock News - StockTitan
Jefferies starts Inhibikase Therapeutics shares with Buy on drug potential - Investing.com
Jefferies starts Inhibikase Therapeutics shares with Buy on drug potential By Investing.com - Investing.com Canada
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Hedge Fund and Insider Trading News: D.E. Shaw, David Einhorn, Bill Ackman, Crispin Odey, Ken Griffin, Elliott Investment Management, Bridgewater Associates, Inhibikase Therapeutics Inc (IKT), Micron Technology Inc (MU), and More - Insider Monkey
Inhibikase Therapeutics director Bellini acquires $2m in stock By Investing.com - Investing.com South Africa
Director Arvind Kush Acquires 145,000 Shares of Inhibikase Thera - GuruFocus.com
Inhibikase therapeutics director Amit Munshi buys $500k in shares - Investing.com India
Inhibikase therapeutics director Amit Munshi buys $500k in shares By Investing.com - Investing.com Australia
Inhibikase Therapeutics director Bellini acquires $2m in stock - Investing.com India
Inhibikase therapeutics director Kush Arvind buys $198,650 in stock - Investing.com
Inhibikase Therapeutics Secures Funding and Strengthens Leadership - Yahoo Finance
Inhibikase (IKT) Stock Climbs After-Market Following Key Financing - Stocks Telegraph
Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance
Perceptive Advisors LLC Acquires New Stake in Inhibikase Therape - GuruFocus.com
Inhibikase Therapeutics stock rises after pricing $110M private offering - MSN
IKTInhibikase Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Inhibikase Therapeutics Announces Closing of up to $275 - GlobeNewswire
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension - StockTitan
Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):